vs
Artisan Partners Asset Management Inc.（APAM）与Apellis Pharmaceuticals, Inc.（APLS）财务数据对比。点击上方公司名可切换其他公司
Artisan Partners Asset Management Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.7倍（$335.5M vs $199.9M），Artisan Partners Asset Management Inc.净利率更高（35.2% vs -29.5%，领先64.7%），Artisan Partners Asset Management Inc.同比增速更快（12.9% vs -5.9%），Artisan Partners Asset Management Inc.自由现金流更多（$171.6M vs $-14.3M），过去两年Artisan Partners Asset Management Inc.的营收复合增速更高（12.7% vs 7.7%）
阿蒂森伙伴资产管理公司（Artisan Partners）是总部位于美国威斯康星州密尔沃基的资产管理机构，除美国本土外，还在都柏林、香港、伦敦、新加坡、悉尼设有办公室，为全球客户提供专业的资产管理服务。
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
APAM vs APLS — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $335.5M | $199.9M |
| 净利润 | $118.1M | $-59.0M |
| 毛利率 | — | — |
| 营业利润率 | 39.2% | -25.6% |
| 净利率 | 35.2% | -29.5% |
| 营收同比 | 12.9% | -5.9% |
| 净利润同比 | 34.9% | -62.2% |
| 每股收益（稀释后） | $1.36 | $-0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $335.5M | $199.9M | ||
| Q3 25 | $301.3M | $458.6M | ||
| Q2 25 | $282.7M | $178.5M | ||
| Q1 25 | $277.1M | $166.8M | ||
| Q4 24 | $297.1M | $212.5M | ||
| Q3 24 | $279.6M | $196.8M | ||
| Q2 24 | $270.8M | $199.7M | ||
| Q1 24 | $264.4M | $172.3M |
| Q4 25 | $118.1M | $-59.0M | ||
| Q3 25 | $66.8M | $215.7M | ||
| Q2 25 | $67.6M | $-42.2M | ||
| Q1 25 | $61.1M | $-92.2M | ||
| Q4 24 | $87.5M | $-36.4M | ||
| Q3 24 | $73.0M | $-57.4M | ||
| Q2 24 | $57.6M | $-37.7M | ||
| Q1 24 | $59.5M | $-66.4M |
| Q4 25 | 39.2% | -25.6% | ||
| Q3 25 | 33.8% | 48.7% | ||
| Q2 25 | 28.2% | -18.6% | ||
| Q1 25 | 31.2% | -50.0% | ||
| Q4 24 | 36.7% | -12.3% | ||
| Q3 24 | 33.3% | -24.0% | ||
| Q2 24 | 32.0% | -14.7% | ||
| Q1 24 | 29.4% | -36.0% |
| Q4 25 | 35.2% | -29.5% | ||
| Q3 25 | 22.2% | 47.0% | ||
| Q2 25 | 23.9% | -23.6% | ||
| Q1 25 | 22.1% | -55.3% | ||
| Q4 24 | 29.5% | -17.1% | ||
| Q3 24 | 26.1% | -29.2% | ||
| Q2 24 | 21.3% | -18.9% | ||
| Q1 24 | 22.5% | -38.5% |
| Q4 25 | $1.36 | $-0.40 | ||
| Q3 25 | $0.93 | $1.67 | ||
| Q2 25 | $0.94 | $-0.33 | ||
| Q1 25 | $0.82 | $-0.74 | ||
| Q4 24 | $0.99 | $-0.30 | ||
| Q3 24 | $1.03 | $-0.46 | ||
| Q2 24 | $0.80 | $-0.30 | ||
| Q1 24 | $0.84 | $-0.54 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $466.2M |
| 总债务越低越好 | $190.0M | — |
| 股东权益账面价值 | $438.8M | $370.1M |
| 总资产 | $1.6B | $1.1B |
| 负债/权益比越低杠杆越低 | 0.43× | — |
8季度趋势，按日历期对齐
| Q4 25 | — | $466.2M | ||
| Q3 25 | — | $479.2M | ||
| Q2 25 | — | $370.0M | ||
| Q1 25 | — | $358.4M | ||
| Q4 24 | — | $411.3M | ||
| Q3 24 | — | $396.9M | ||
| Q2 24 | — | $360.1M | ||
| Q1 24 | — | $325.9M |
| Q4 25 | $190.0M | — | ||
| Q3 25 | $190.0M | — | ||
| Q2 25 | $200.0M | — | ||
| Q1 25 | $200.0M | — | ||
| Q4 24 | $200.0M | — | ||
| Q3 24 | $200.0M | — | ||
| Q2 24 | $200.0M | — | ||
| Q1 24 | $200.0M | $93.1M |
| Q4 25 | $438.8M | $370.1M | ||
| Q3 25 | $402.1M | $401.2M | ||
| Q2 25 | $381.8M | $156.3M | ||
| Q1 25 | $356.5M | $164.2M | ||
| Q4 24 | $388.9M | $228.5M | ||
| Q3 24 | $372.1M | $237.1M | ||
| Q2 24 | $341.2M | $264.3M | ||
| Q1 24 | $320.3M | $266.7M |
| Q4 25 | $1.6B | $1.1B | ||
| Q3 25 | $1.6B | $1.1B | ||
| Q2 25 | $1.4B | $821.4M | ||
| Q1 25 | $1.4B | $807.3M | ||
| Q4 24 | $1.6B | $885.1M | ||
| Q3 24 | $1.6B | $901.9M | ||
| Q2 24 | $1.5B | $904.5M | ||
| Q1 24 | $1.5B | $831.9M |
| Q4 25 | 0.43× | — | ||
| Q3 25 | 0.47× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.56× | — | ||
| Q4 24 | 0.51× | — | ||
| Q3 24 | 0.54× | — | ||
| Q2 24 | 0.59× | — | ||
| Q1 24 | 0.62× | 0.35× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $172.0M | $-14.2M |
| 自由现金流经营现金流 - 资本支出 | $171.6M | $-14.3M |
| 自由现金流率自由现金流/营收 | 51.2% | -7.1% |
| 资本支出强度资本支出/营收 | 0.1% | 0.1% |
| 现金转化率经营现金流/净利润 | 1.46× | — |
| 过去12个月自由现金流最近4个季度 | $420.6M | $45.0M |
8季度趋势，按日历期对齐
| Q4 25 | $172.0M | $-14.2M | ||
| Q3 25 | $40.4M | $108.5M | ||
| Q2 25 | $50.9M | $4.4M | ||
| Q1 25 | $157.9M | $-53.4M | ||
| Q4 24 | $372.8M | $19.4M | ||
| Q3 24 | $112.8M | $34.1M | ||
| Q2 24 | $75.9M | $-8.3M | ||
| Q1 24 | $147.0M | $-133.0M |
| Q4 25 | $171.6M | $-14.3M | ||
| Q3 25 | $40.4M | $108.3M | ||
| Q2 25 | $50.9M | $4.4M | ||
| Q1 25 | $157.7M | $-53.4M | ||
| Q4 24 | $371.3M | $19.3M | ||
| Q3 24 | $112.4M | — | ||
| Q2 24 | $75.2M | $-8.4M | ||
| Q1 24 | $146.9M | $-133.3M |
| Q4 25 | 51.2% | -7.1% | ||
| Q3 25 | 13.4% | 23.6% | ||
| Q2 25 | 18.0% | 2.5% | ||
| Q1 25 | 56.9% | -32.0% | ||
| Q4 24 | 125.0% | 9.1% | ||
| Q3 24 | 40.2% | — | ||
| Q2 24 | 27.8% | -4.2% | ||
| Q1 24 | 55.6% | -77.3% |
| Q4 25 | 0.1% | 0.1% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | 0.0% | ||
| Q1 25 | 0.1% | 0.0% | ||
| Q4 24 | 0.5% | 0.0% | ||
| Q3 24 | 0.1% | 0.0% | ||
| Q2 24 | 0.2% | 0.0% | ||
| Q1 24 | 0.0% | 0.2% |
| Q4 25 | 1.46× | — | ||
| Q3 25 | 0.60× | 0.50× | ||
| Q2 25 | 0.75× | — | ||
| Q1 25 | 2.58× | — | ||
| Q4 24 | 4.26× | — | ||
| Q3 24 | 1.54× | — | ||
| Q2 24 | 1.32× | — | ||
| Q1 24 | 2.47× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APAM
暂无分部数据
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
